Sugi Predict

Sugi Predict / Compounds / SCHEMBL299611

SCHEMBL299611

SCHEMBL299611

CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(S(N)(=O)=O)cc4)cc23)c1F

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 12/20 0.86
▸ CYP2C9 P11712 10/20 0.86
▸ BRAF P15056 2/20 0.85
▸ CYP3A4 P08684 3/20 0.84
▸ RIPK2 O43353 1/20 0.83
▸ ABCB11 O95342 1/20 0.83
▸ EGFR P00533 1/20 0.83
▸ KRAS P01116 1/20 0.83
▸ RAF1 P04049 1/20 0.83
▸ PGR P06401 1/20 0.83
▸ RET P07949 1/20 0.83
▸ CHRM2 P08172 1/20 0.83
▸ ADORA3 P0DMS8 1/20 0.83
▸ ARAF P10398 1/20 0.83
▸ CHRM1 P11229 1/20 0.83
▸ CHRM3 P20309 1/20 0.83
▸ FECH P22830 1/20 0.83
▸ KDR P35968 1/20 0.83
▸ MAP2K2 P36507 1/20 0.83
▸ TGFBR2 P37173 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29898551 1.00 CYP2C19 (0.86) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL7874403 0.93 CYP2C19 (0.88) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL295650 0.93 CYP2C19 (1.00) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL20294636 0.92 BRAF (1.00) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL298927 0.92 BRAF (0.89) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL27103518 0.91 CYP2C19 (0.82) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL27103816 0.91 CYP2C19 (0.85) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL298257 0.91 CYP2C19 (1.00) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL12891936 0.91 BRAF (1.00) CYP2C19CYP2C9BRAFCYP3A4RIPK2
SCHEMBL855840 0.91 BRAF (0.87) CYP2C19CYP2C9BRAFCYP3A4RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3823968-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HepaRegeniX GmbH (DE) 2021-05-26 — — EP claimed
WO-2020016243-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2020-01-23 — — WO claimed
US-8198273-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-06-12 — — US claimed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US claimed
CN-112424201-B Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death 海帕瑞吉尼克斯股份有限公司 2024-04-02 — — CN disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 — — US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 — — US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 — — US disclosed
US-20220281864-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2022-09-08 — — US disclosed
EP-3823968-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HepaRegeniX GmbH (DE) 2021-05-26 — — EP disclosed
WO-2020016243-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH HEPAREGENIX GMBH (DE) 2020-01-23 — — WO disclosed
US-20120245174-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2012-09-27 — — US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 — — US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 — — US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 — — US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 — — EP disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 — — WO disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAPK7, MAPK14 CYP2C19 2763/4885CYP2C9 1742/4885BRAF 64/4885
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CYP2C19 2730/4885CYP2C9 2176/4885BRAF 1/4885
US-20220281864-A1 PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH MAPK4, MAPK7, MAPK14 CYP2C19 2855/4885CYP2C9 1814/4885BRAF 65/4885
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, ARAF, RAF1 CYP2C19 2678/4885CYP2C9 2237/4885BRAF 1/4885
US-20120245174-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR BRAF, ARAF, RAF1 CYP2C19 2678/4885CYP2C9 2237/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.